2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Non-Biological Therapies, Anticoagulant Drugs, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Thrombotic Disorders, Immunology, Infectious Diseases, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Study Population, Human, Adult, Pediatric
PAPER

4840 Characteristics and post-transplant outcomes of antiphospholipid syndrome in kidney transplant recipients: A Mayo Clinic enterprise experience

Isabela W Chang, MD, Rachana Punukollu, M.B.B.S2, Duke J. Butterfield, MA3, Andrew Bentall, MD4, Rose Mary Attieh, MD5, Girish K. Mour, M.B.B.S6, Surbhi Shah, MBBS, MD7
1 Mayo Clinic, Scottsdale, Arizona, United States
2 Mayo Clinic, Phoenix, Arizona, United States
3 Mayo Clinic, Scottsdale, Arizona, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Jacksonville, Florida, United States
6 Mayo Clinic, Phoenix, Arizona, United States
7 Mayo Clinic, Phoenix, Arizona, United States

Background:

Antiphospholipid syndrome (APS) is an autoimmune prothrombotic disorder associated with recurrent significant arterial and venous thrombosis, resulting in substantial morbidity and mortality. Kidney transplantation is the preferred treatment for end-stage renal disease, yet recipients with APS remain at increased risk for perioperative thrombotic and bleeding complications that may adversely affect allograft and patient outcomes. Despite advances in perioperative anticoagulation strategies, real-world data describing outcomes following kidney transplantation in patients with APS remain limited. We sought to characterize clinical features, perioperative management, and post-transplant outcomes in APS kidney transplant recipients across the Mayo Clinic enterprise.

Methods:

We performed a retrospective cohort study across the Mayo Clinic enterprise (Arizona, Minnesota, Florida). Adult patients (≥18 years) with antiphospholipid antibody positivity and/or antiphospholipid syndrome who underwent kidney transplantation between January 1, 2011, and December 31, 2023, were identified. They were eligible if they had at least one of the following pre-transplant characteristics: (1.) a history of antiphospholipid syndrome (APS), (2.) positive antiphospholipid antibody testing (titer >40 units), (3.) positive or indeterminate lupus anticoagulant testing. Patients undergoing repeat kidney transplantation or simultaneous multiorgan transplantation were excluded. Demographic characteristics, APS serologies, perioperative anticoagulation strategies, and post-transplant outcomes were collected through detailed chart review. Demographic characteristics, APS serologies, and perioperative anticoagulation strategies, including pre-transplant anticoagulation, perioperative heparin bridging, and post-transplant anticoagulation use (0–30, 31–90, and 91–365 days), were collected through detailed chart review. Outcomes of interest included post-transplant thrombotic events, bleeding complications, re- exploration, and allograft thrombosis. Bleeding events were classified according to the International Society on Thrombosis and Hemostasis (ISTH) criteria, and APS was defined according to the 2023 ACR/EULAR classification criteria. Patient characteristics and outcomes were summarized using descriptive statistics.

Results:

A total of 124 kidney transplant recipients met study inclusion criteria, including 44 (35.5%) with a history of APS and 80 (64.5%) without APS. Compared with recipients without APS, patients with APS were younger, more frequently female, and more likely to have ESRD secondary to lupus nephritis (59.1% vs. 23.8%, p<0.001). They also had a significantly higher prevalence of prior thrombotic events (63.6% vs. 35.0%, p=0.002), particularly deep venous thrombosis (43.2% vs. 17.5%, p=0.002), and were more likely to receive anticoagulation before transplantation (65.1% vs. 24.4%, p<0.001). APS recipients were managed with more intensive perioperative anticoagulation, including greater use of heparin bridging (50.0% vs. 27.5%, p=0.012), and were more likely to remain on anticoagulation during the first 30 days (77.3% vs. 35.0%), 31–90 days (68.2% vs. 30.0%), and 91–365 days (61.4% vs. 33.8%) following transplantation (all p≤0.003). Despite their higher baseline thrombotic risk, post-transplant thrombotic complications remained uncommon, with no significant differences in early or late venous or arterial thromboembolic events, allograft thrombosis, or re-exploration rates between groups. Similarly, post- transplant bleeding rates, including both allograft-related and non-allograft-related bleeding through 90 days, were comparable despite substantially greater anticoagulation exposure in the APS cohort.

Conclusion:

Kidney transplant recipients with APS require significantly more intensive perioperative and long-term anticoagulation because of their higher baseline thrombotic risk. Despite this, post-transplant thrombotic events, bleeding complications, and re-exploration rates were similar to recipients without APS, suggesting that individualized anticoagulation strategies can be implemented safely in this high-risk population.

Isabela W Chang, MD: No relevant conflicts of interest to declare.